Literature DB >> 10037363

Pyelolithotomy improves while extracorporeal lithotripsy impairs kidney function.

D Eterović1, L Juretić-Kuscić, V Capkun, Z Dujić.   

Abstract

PURPOSE: Extracorporeal shock wave lithotripsy (ESWL) causes acute depression of kidney function, which chronically returns to baseline levels. This sequala could indicate chronic regression of acute lesions or a balance between lesions and relief of obstruction. We compared changes in kidney function 1 week and 3 months after ESWL and pyelolithotomy.
MATERIALS AND METHODS: A group of 17 women and 13 men 28 to 71 years old with 0.6 to 3 cm. stones received 1,800 to 3,200 shock waves by an electromagnetic lithotriptor. Another group of 21 women and 9 men 35 to 76 years old with 2.5 to 3.8 cm. stones underwent Gil-Vernet intra-sinus pyelolithotomy. Split renal plasma flow, glomerular filtration rate and mean parenchymal transit times of nonreabsorbable filtrate solutes were measured by dual gamma camera renography, and plasma clearances of 99mtechnetium diethylenetriaminepentaacetic acid and 131orthoiodohippurate acid.
RESULTS: ESWL caused acute deterioration and chronic restoration of baseline parameters of the treated kidney, and small but sometimes irreversible damage to plasma flow to the untreated kidney, especially in obese patients. In contrast, pyelolithotomy acutely and chronically improved function of the treated kidney, and normalized parenchymal transit times of radiotracers.
CONCLUSIONS: ESWL does not achieve substantial improvements in kidney function, which can be achieved by other methods of stone removal.

Entities:  

Mesh:

Year:  1999        PMID: 10037363

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Impact of stone removal on renal function: a review.

Authors:  Kyle Wood; Tristan Keys; Patrick Mufarrij; Dean G Assimos
Journal:  Rev Urol       Date:  2011

2.  A decrease in blood pressure following pyelolithotomy but not extracorporeal lithotripsy.

Authors:  Davor Eterović; Marijan Situm; Ljubica Juretić-Kuscić; Zeljko Dujić
Journal:  Urol Res       Date:  2004-12-24

3.  Assessing the efficiency of extracorporeal shockwave lithotripsy for stones in renal units with impaired function: a prospective controlled study.

Authors:  Anand Srivastava; Tapan Sinha; S C Karan; A S Sandhu; S K Gupta; G S Sethi; R Talwar; V Narang; N Adlakha; A Agarwal
Journal:  Urol Res       Date:  2006-02-15

4.  Wrong perspective obscures the adverse effects of shock-wave lithotripsy.

Authors:  Davor Eterović; Marijan Situm; Vinko Marković; Ante Punda
Journal:  Urolithiasis       Date:  2012-12-23       Impact factor: 3.436

5.  Retroperitoneal laparoscopic pyelolithotomy versus extra corporeal shock-wave lithotripsy for management of renal stones.

Authors:  Jagdish Chander; Nikhil Gupta; Pawanindra Lal; Pawan Lal; Vinod K Ramteke
Journal:  J Minim Access Surg       Date:  2010-10       Impact factor: 1.407

6.  Urinary obstruction depresses erythropoiesis which recovers after parenchyma-saving surgery but not SWL.

Authors:  Davor Eterović; Marijan Situm; Ante Punda; Vinko Marković; Slaven Kokić
Journal:  Urol Res       Date:  2009-12-01

7.  Treatment of renal calculi by lithotripsy: minimizing short-term shock wave induced renal damage by using antioxidants.

Authors:  Khaleel A Al-Awadi; Elijah O Kehinde; Issa Loutfi; Olusegun A Mojiminiyi; Adel Al-Hunayan; Hamdy Abdul-Halim; Ahmed Al-Sarraf; Anjum Memon; Mathew P Abraham
Journal:  Urol Res       Date:  2007-12-07

8.  Retroperitoneal pyelolithotomy for management of renal calculi.

Authors:  Jagdish Chander; Manav Suryavanshi; Pawan Lal; Lakvinder Singh; V K Ramteke
Journal:  JSLS       Date:  2005 Jan-Mar       Impact factor: 2.172

9.  Postoperative Renal Outcomes of Patients Receiving Percutaneous Nephrolithotomy versus Pyelolithotomy: A Population-Based Cohort Study.

Authors:  Fang-Ting Chen; Fu-Chao Liu; Chih-Wen Cheng; Jr-Rung Lin; Huang-Ping Yu
Journal:  Biomed Res Int       Date:  2018-05-02       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.